CD7 and acute myeloid leukemia: We found that KMT2Ar AML was characterized by lower expression of CD7 (median: 4 vs 14%, P < 0.001), CD13 (median: 58 vs 72%, P < 0.001), and CD34 (median: 16 vs 34%, P < 0.001), and higher expression of CD33 (median: 94 vs 85%, P < 0.001) (Supplemental Fig. 3).